Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Svar på framväxande antimikrobiell resistens med inneslutningsmikrobiotaterapi (REACT)

3 november 2026 uppdaterad av: Michael Woodworth, Emory University

Svar på framväxande antimikrobiell resistens med inneslutningsmikrobiotaterapi

REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO). REACT is designed to assess the safety and efficacy of MT administered to subjects colonized with a MDRO. The overarching hypothesis is that MT can reduce MDRO colonization with safety that is comparable to observation.

Studieöversikt

Status

Aktiv, inte rekryterande

Detaljerad beskrivning

REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO) in patients admitted to long-term care facilities. REACT is designed to test the safety and efficacy of instillation of donor intestinal microbiota.

Patients admitted to long-term care facilities (e.g. long-term acute care hospitals and ventilator-capable skilled nursing facilities) found to be MDRO colonized during prevalence screening activities performed in the related APPS study.

Facilities undergo prevalence sampling that involves participant peri-rectal, inguinal, and stool sampling to estimate the prevalence of targeted MDROs (CRE, ESBL, VRE, MDRP) under the accompanying APPS protocol. Patients who are positive with at least one targeted MDRO are eligible for an Emory manufactured MT product (via rectal enema or feeding tube), or observation followed by repeat sampling at Days 7, 14, 21, and 28. Participants will be followed with collection of data on adverse events/safety/changes in medications at Days 0, 7, 14, 21, 28, and followed up once a month for 6 months, after MT administration.

Studietyp

Interventionell

Inskrivning (Faktisk)

58

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30329
        • A.G Rhodes Wesley Woods
      • Decatur, Georgia, Förenta staterna, 30030
        • Emory Long Term Acute Care (LTAC)
    • Illinois
      • Hinsdale, Illinois, Förenta staterna, 60521
        • RML Specialty Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19146
        • Penn Medicine Rittenhouse

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Be able (or have available a Legal Authorized Representative who is able) to understand and sign a written informed consent document.
  2. Be at least 18 years old at the time of consent.
  3. Be able to comply with all study protocol requirements, including able to receive MT as retention enema or via enteral feeding tube and be available for the duration of the study follow up.
  4. Be colonized with a target MDRO (CRE, VRE, ESBL, MDR Pseudomonas) as detected by bacterial culture of stool or peri-rectal swab (collected in companion APPS facility prevalence sampling protocol).
  5. Be able to discontinue or complete planned courses of antibiotics, probiotics, and other microbiota restoration therapies by Day -1 and not resume until after Day 28.
  6. The effects of the MT on the developing human fetus are unknown. For this reason, persons of child-bearing potential (POCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
  7. Agree to refrain from receptive anal intercourse until the last biological specimen (stool sample or peri-rectal swab) is collected (Day 28).

Exclusion Criteria:

  1. Are pregnant, breastfeeding, lactating, or planning a pregnancy during study duration (through 4 weeks after the last dose of investigational product, or MT), if POCBP.

  2. Have known uncontrolled intercurrent illness(es):

    1. Symptomatic congestive heart failure
    2. Acute coronary syndrome
    3. Cardiac arrhythmia
    4. Untreated in-situ colorectal cancer
    5. Toxic megacolon
    6. Ileus
    7. Positive stool studies without completion of treatment course (including ova and parasites, Salmonella spp, Shigella, Campylobacter, and other enteropathogens).
    8. other acute illness that in the opinion of the investigator could affect the safety of the participant or make study data uninterpretable.
  3. Are on systemic antibiotics for any reason other than treatment of recent MDRO infection or clear anticipated need for antibiotics during the follow up period that cannot be rescheduled (e.g. fluoroquinolone prophylaxis for percutaneous nephrostomy tube exchange, prolonged antibiotic course for endocarditis). Participants must complete the planned antibiotic course by study Day -1.

  4. Have a compromised immune system, defined as:

    1. AIDS with CD4+ T-cell count <200 and detectable HIV viral load on most recent assay.
    2. Absolute neutrophil count (ANC) <1,000 neutrophils / mL on day of enrollment.
    3. Active malignancy requiring intensive induction chemotherapy, radiotherapy, or biologic treatment within 2 months prior to enrollment.
    4. History of hematopoietic cell transplantation, either allogeneic or autologous in the last 1 year.
  5. Have a history of significant food allergy that led to anaphylaxis or hospitalization.

  6. Have a life expectancy of 24 weeks or less

  7. Have any condition that, in the opinion of the investigator, might interfere with study objectives or limit compliance with study requirements, including but not limited to:

    1. Known active intravenous drug or alcohol abuse
    2. Uncontrolled psychiatric illness
    3. Social situations (e.g. incarceration)
  8. Received an interventional agent (drug, device, or procedure) within 28 days prior to enrollment.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Group 1: microbiota therapy (MT)

Group 1 will offer Microbiome therapeutic (MT) to all MDRO-positive patients (i.e., intervention condition).

Participants will receive an Emory-manufactured MT product, delivered as 250mL via rectal enema or 30mL instillation via an existing functioning feeding tube with the rate adjusted to participant tolerance. Participants will receive three doses over the first seven days of the study.

Andra namn:
  • Fekal mikrobiotatransplantation (FMT)
  • Mikrobiom terapeutisk (MT)
  • Pall från friska donatorer i saltlösningssuspension med 9 volymprocent glycerol
Inget ingripande: Group 2: Observation

Group 2 will be assigned to observation.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Difference in number of solicited Adverse Events (AEs)
Tidsram: Day 0, Day 7 post-intervention

Difference in number of solicited AEs between Day 0 and Day 7 in AMG-treated vs Observation participants.

Day 0, Day 7 post-intervention
Difference in severity of solicited AEs
Tidsram: Day 0, Day 7 post-intervention

Difference in severity of solicited AEs will be compared in AMG-treated vs Observation participants. Graded as mild, moderate or severe, up to 7 days post-intervention.

Day 0, Day 7 post-intervention
Difference in number of unsolicited AEs
Tidsram: Day 0, Day 28 post-intervention

Difference in number of unsolicited AEs between Day 0 and Day 28 in AMG-treated vs Observation participants.

Day 0, Day 28 post-intervention
Difference in severity of unsolicited AEs
Tidsram: Day 0 and Day 28

Difference in severity of unsolicited AEs will be collected between Day 0 and Day 28. Graded as mild, moderate or severe and compared in AMG-treated vs Observation participants

Day 0 and Day 28
Number of participants by composite MDRO Colonization and survival status
Tidsram: Day 28 post-intervention

Participants will be classified into one of three ordinal categories: (1) alive without MDRO colonization, (2) alive with MDRO colonization, or (3) deceased. MDRO colonization is defined as a stool culture at Day 28 positive for any target multidrug-resistant organism (MDRO).

Day 28 post-intervention

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Count of serious AEs (SAEs)
Tidsram: Day 180 (6 months)

Count of serious AEs (SAEs) between Day 0 and Month 6 (Day 180) censored by last telephone visits or death, whichever is later.

Day 180 (6 months)
Count of AEs of Special Interest (AESIs)
Tidsram: Day 180 (6 months)

Count of AEs of Special Interest (AESIs) at day Day 180, censored by last telephone visit or death, whichever is later.

Day 180 (6 months)
Number of participants by category-specific MDRO Colonization and survival status
Tidsram: Day 28

Participants will be classified into one of three ordinal categories: (1) survival without colonization of the category-specific multidrug-resistant organism (MDRO), (2) survival with colonization of the category-specific MDRO, or (3) deceased. Category-specific MDRO colonization is defined as a stool culture at Day 28 positive for the category-specific MDRO being evaluated (e.g., ESBL, CRE, MDRP, or VRE).

Day 28

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Michael Woodworth, MD, Emory University

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

13 januari 2025

Primärt slutförande (Faktisk)

8 juli 2026

Avslutad studie (Beräknad)

1 januari 2027

Studieregistreringsdatum

Först inskickad

13 mars 2024

Först inskickad som uppfyllde QC-kriterierna

13 mars 2024

Första postat (Faktisk)

20 mars 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • STUDY00007230
  • U54CK000601 (U.S.S. NIH-anslag/kontrakt)
  • 2024P008055 (Annan identifierare: Emory IRB)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Deidentified participant solicited adverse event and serious adverse event data will be shared.

Isolate genomic data and participant metagenomic data will be shared in public repositories (NCBI) at time of publication

Tidsram för IPD-delning

Data will become available at time of publication.

Kriterier för IPD Sharing Access

Sequence data access will not be restricted. Additional participant-level data will be shared by review of PI of proposing investigators and appropriate ethical approval (e.g. IRB) if any.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera